
Please try another search
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Kwok-Kin Wong | - | - | Member of Scientific Advisory Board |
Anthony G. Letai | - | - | Member of Scientific Advisory Board |
Karan S. Takhar | 34 | 2017 | Independent Director |
Jan Skvarka | 58 | 2022 | Independent Director |
Ross L. Levine | 53 | - | Member of Scientific Advisory Board |
Enoch K. Kariuki | 43 | 2021 | Independent Director |
David Michael Johnson | 59 | 2020 | Independent Director |
Scott D. Myers | 59 | 2024 | Chairman of the Board |
Funda Meric-Bernstam | - | 2023 | Member of Scientific Advisory Board |
Julie M. Eastland | 61 | 2024 | CEO, President & Director |
Luke N. Walker | 53 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review